Astra Zeneca who have a joint venture with US pharma company Merck, has said the phase three trials of Lynparza which is a new drug for pancreatic cancer said patients trialling the drug went for 7.4 months without their illness worsening.
Jose Baselga, of AstraZenecaโs oncology research department said, โThese unprecedented results raise new hope for patients that haveย seen little progress over a long period of time.
โFrom as early as six months after initiation, more than twice as manyย patients takingย Lynparzaย lived without progression of their disease compared to those on placebo and we are now working with regulatory authorities to bringย Lynparzaย toย patients as quickly as possible.โ
Hedy L Kindler MD, co-principal investigator of the trial and Professor of Medicine at University of Chicago Medicine said, โDespite efforts to identify therapies, targeted or combination treatments to improve patient outcomes, pancreatic cancer remains an area of high unmet need.โ
Less than 3% of pancreatic cancer patients survive more than five years, the pharma giant hopes Lynparza could mark a change.
Leave a Comment